Skip to main content
OpenTrials
Completed

NCT Number: NCT03678584

Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Chaetoglobosin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Chaetoglobosin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Qena Fertility Center, Qina, Qena Governorate, Egypt

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All ICSI participants agreed

Exclusion criteria

-

Treatment and study plan

Medium Supplemented with Chaetoglobosin A

Other

A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate

Primary outcomes

  1. Oocyte Survival after ICSI

    Time frame: two days

    Survived oocytes per MII injected

Secondary outcomes

  1. Fertilization rate

    Time frame: 6 days of culture

  2. Rate of top-quality embryo

    Time frame: 6 days of culture

    Rate of top-quality embryo per fertilized oocytes

  3. blastocyst formation and quality

    Time frame: 6 days of culture

    Number of formed blastocyst and high-quality blastocyst per fertilized oocytes

  4. blastocyst utilization rate

    Time frame: 6 days of culture

    Number of transferred and vitrified embryos per fertilized oocytes

  5. clinical pregnancy rate

    Time frame: 7 weeks

    Number of pregnant women per recruited cycles

  6. Implantation rate

    Time frame: 7 weeks

    sacs with a heartbeat per embryo transferred

  7. Ongoing pregnancy rate

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Ibn Sina Hospital

Other Gov

Collaborators

  • Banoon IVF Center
  • Qena Fertility Center

Registry information

Official study title

Chaetoglobosin A Supplementation to ICSI Handling Medium

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 19, 2018
Registry last updated
May 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.